Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Racial and ethnic disparities in retinoblastoma treatment options
Vivienne S. Hau, MD, PhD, a vitreoretinal surgeon and faculty member at the Bernard J Tyson School of Medicine, Kaiser Permanente Med School, and also at the California University of School of Medicine, presented research on racial and ethnic disparities…
Neighborhood-level characteristics associated with delay in surgery and loss to follow-up
Sally S. Ong, MD, an assistant professor of ophthalmology at Atrium Health Wake Forest Baptist School of Medicine, presented research examining the relationship between neighborhood-level social determinants of health and disease severity in patients with tractional retinal detachments (TRD) associated…
Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin
(Image credit: AdobeStock/Drazen) K. Chalam MD, PhD, MBA, FRCS(C), FASRS, presented, “Dropless vitrectomy with suprachoroidal triamcinolone-moxifloxacin: A comparative analysis of safety and efficacy with standard-of-care topical drops” at the 2025 annual scientific meeting of the American Society of Retina Specialists.…
Alcon presenting at APACRS 2025
(Image credit: ©RealityImages/AdobeStock) Alcon announced presentations during the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting. The company will showcase four symposia, lead 10 medical affairs scientific exchange presentations, and offer a hands-on experience zone booth.1 APACRS…
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…
Associations between androgen exposure, PCOS, and transmasculine individuals with central serous chorioretinopathy
Danny A. Mammo, MD, a vitreoretinal surgeon and uveitis specialist at the Cole Eye Institute at Cleveland Clinic, presented research on the association between androgen exposure and central serous chorioretinopathy (CSCR) at the 2025 scientific meeting of the American Society…
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients – GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients GlobeNewswire Source: Author: | Date: 2025-08-21 05:32:00 Source: Author: | Date: 2025-08-21 05:32:00
Natural molecule discovery could help glaucoma patients – Medical Xpress
Natural molecule discovery could help glaucoma patients Medical Xpress Source: Author: | Date: 2025-08-20 18:00:00 Source: Author: | Date: 2025-08-20 18:00:00
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…